骨髓增生异常综合征的诊治最新进展

doi:10.16150/j.1671-2870.2019.06.004

摘要/Abstract

中图分类号:

R733.3

吴凌云, 常春康. 骨髓增生异常综合征的诊治最新进展[J]. 诊断学理论与实践, 2019, 18(06): 623-629.

参考文献 42

[1]	Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions[J]. Oncotarget, 2017, 8(43):73483-73500. doi: 10.18632/oncotarget.19008 pmid: 29088721
[2]	Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405. doi: 10.1182/blood-2016-03-643544 URL
[3]	Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes[J]. N Engl J Med, 2014, 371(26):2488-2498. doi: 10.1056/NEJMoa1408617 URL
[4]	Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis[J]. Nat Genet, 2012, 44(11):1179-1181. doi: 10.1038/ng.2413 URL
[5]	Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes[J]. Blood, 2015, 126(1):9-16. doi: 10.1182/blood-2015-03-631747 pmid: 25931582
[6]	Malcovati L, Gallì A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia[J]. Blood, 2017, 129(25):3371-3378. doi: 10.1182/blood-2017-01-763425 pmid: 28424163
[7]	Hansen JW, Westman MK, Sjö LD, et al. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes[J]. Am J Hematol, 2016, 91(12):1234-1238. doi: 10.1002/ajh.24554 URL
[8]	Balleari E, Clavio M, Arboscello E, et al. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes[J]. Leuk Res, 2011, 35(11):1472-1476. doi: 10.1016/j.leukres.2011.05.025 URL
[9]	张宏丽, 秦铁军, 徐泽锋, 等. 重组人EPO治疗较低危骨髓增生异常综合征的临床疗效分析[J]. 中华血液学杂志, 2014, 35(1):18-23.
[10]	Garelius HK, Johnston WT, Smith AG, et al. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome[J]. J Intern Med, 2017, 281(3):284-299. doi: 10.1111/joim.12579 pmid: 27926979
[11]	List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J]. N Engl J Med, 2006, 355(14):1456-1465. doi: 10.1056/NEJMoa061292 URL
[12]	Santini V, Almeida A, Giagounidis A, et al. Randomized phase Ⅲ study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents[J]. J Clin Oncol, 2016, 34(25):2988-2996. doi: 10.1200/JCO.2015.66.0118 URL
[13]	Cadenas-Cadenas FL, Lumbreras E, Xicoy B, et al.Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q)- Preliminary Blinded Analysis of the European Sintra-REV Trial[A].[60th American Society of Hematology Annual Meeting oral presentation]Blood 2018, 132(suppl 1):468.
[14]	Xiao L, Qi Z, Qiusheng C, et al. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression[J]. Am J Hematol, 2012, 87(1):26-31. doi: 10.1002/ajh.22184 pmid: 22038646
[15]	Stahl M, Bewersdorf JP, Giri S, et al. Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis[J]. Haematologica,2019,pii:haematol. 2019.219345.
[16]	Zeidan AM, Zhu W, Stahl M, et al. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis[J]. Leuk Lymphoma, 2019:1-7.
[17]	Baek DW, Lee YJ, Kim H, et al. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts[J]. Ann Hematol, 2018, 97(12):2309-2317. doi: 10.1007/s00277-018-3458-7 URL
[18]	Jabbour E, Short NJ, Montalban-Bravo G, et al. Rando-mized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN[J]. Blood, 2017, 130(13):1514-1522. doi: 10.1182/blood-2017-06-788497 pmid: 28774880
[19]	Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial[J]. Lancet Haematol, 2017, 4(3):e127-e136.
[20]	Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia[J]. Cancer, 2014, 120(12):1838-1846. doi: 10.1002/cncr.28663 URL
[21]	Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial[J]. Lancet Haematol, 2018, 5(3):e117-e126.
[22]	Santini V. Anemia as the main manifestation of myelodysplastic syndromes[J]. Semin Hematol, 2015, 52(4):348-356. doi: 10.1053/j.seminhematol.2015.06.002 URL
[23]	Angelucci E, Li J, Greenberg PL, et al. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double-blind telesto study[J]. Blood, 2018, 132:234. doi: 10.1182/blood-2018-99-111134 URL
[24]	Fenaux P, Platzbecker U, Mufti G J, et al. The medalist trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell(RBC) transfusions[J]. Blood, 2018, 132:1.
[25]	Steensma DP, Platzbecker U, van Eygen K, et al. Imetelstat treatment leads to durable transfusion independence (TI) in RBC Transfusion Dependent (TD), Non-Del(5q) lower risk MDS relapsed/refractory to erythropoiesis-stimu-lating agent (ESA) who are lenalidomide (LEN) and HMA naïve[J]. Blood, 2018, 132:463. doi: 10.1182/blood-2018-99-114877 URL
[26]	Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase Ⅲ study[J]. Lancet Oncol. 2009 Mar; 10(3):223-232. doi: 10.1016/S1470-2045(09)70003-8 URL
[27]	Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1):52-57. doi: 10.1182/blood-2006-05-021162 pmid: 16882708
[28]	Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial[J]. J Clin Oncol, 2009, 27(23):3842-3848. doi: 10.1200/JCO.2008.19.6550 pmid: 19528372
[29]	Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada[J]. Br J Haematol, 2018, 181(6):803-815. doi: 10.1111/bjh.15273 URL
[30]	Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes[J]. N Engl J Med, 2016, 375(21):2023-2036. doi: 10.1056/NEJMoa1605949 URL
[31]	Chang CK, Zhao YS, Xu F, et al. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes[J]. Br J Haematol, 2017, 176(4):600-608. doi: 10.1111/bjh.14455 URL
[32]	Xie M, Jiang Q, Li L, et al. HAG (homoharringtonine, cytarabine, G-CSF) regimen for the treatment of acute myeloid Leukemia and myelodysplastic syndrome: A meta-analysis with 2,314 participants[J]. PLoS One, 2016, 11(10):e0164238.
[33]	Wu L, Li X, Chang C, et al. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study[J]. Leuk Lymphoma, 2016, 57(6):1367-1374. doi: 10.3109/10428194.2015.1096351 URL
[34]	中华医学会血液学分会.骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J]. 中华血液学杂志, 2019, 40(2):89-97.
[35]	Garcia-Manero G, Roboz G, Walsh K, et al. Guadecitabine Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial[J]. Lancet Haematol, 2019, 6(6):e317-e327.
[36]	Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethyla-ting drugs (ONTIME): a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(4):496-508. doi: S1470-2045(16)00009-7 pmid: 26968357
[37]	Navada S, Garcia-Manero G, Atallah EL, et al. Phase 2 expansion study of oral rigosertib combined with azacitidine (AZA) in patients (Pts) with higher-risk (HR) myelodysplastic syndromes (MDS): Efficacy and safety results in HMA treatment naǐve & relapsed (Rel)/Refractory (Ref) Patients[J]. Blood, 2018, 132(suppl 1):230. doi: 10.1182/blood-2018-99-119259 URL
[38]	Taylor J, Coleman M, Alvarez J, et al. Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents[J]. Blood, 2018, 132(suppl 1):233. doi: 10.1182/blood-2018-99-113840 URL
[39]	Garcia-Manero G, Sasaki K, Montalban-Bravo G, et al. A phase Ⅱ study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)[J]. Blood, 2018, 132(suppl 1):465.
[40]	Gerds AT, Scott B, Greenberg PL, et al. PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: An initial safety and efficacy analysis[J]. Blood, 2018, 132(suppl 1):466. doi: 10.1182/blood-2018-99-118577 URL
[41]	Brierley CK, Steensma DP. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?[J]. Curr Opin Hematol, 2016, 23(2):167-174. doi: 10.1097/MOH.0000000000000217 URL
[42]	Yahng SA, Kim M, Kim TM, et al. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts[J]. Oncotarget, 2017, 8(7):12342-12354. doi: 10.18632/oncotarget.12511 URL

骨髓增生异常综合征的诊治最新进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何亲羽, 王伟, 陈立芬, 张雪蕾, 董治亚. LHCGR基因突变致家族性男性性早熟2例报告及文献复习[J]. 诊断学理论与实践, 2022, 21(05): 598-605.
[2]	陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[3]	沈银忠. 《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436.
[4]	施霞, 马鑫, 王珍燕, 张晖, 刘少军. 32例人类免疫缺陷病毒感染合并慢性肾病患者的临床病理特征及随访结果分析[J]. 诊断学理论与实践, 2022, 21(04): 437-443.
[5]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[6]	何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546.
[7]	徐子真, 李擎天, 刘湘帆, 李莉, 李惠, 王也飞, 吴洁敏, 陈宁, 梁璆荔, 陈松立, 戴健敏, 宋珍, 丁磊. 实验诊断学在线课程的建立和实践[J]. 诊断学理论与实践, 2022, 21(04): 547-550.
[8]	李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[9]	赵然, 詹维伟, 侯怡卿. 计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394.
[10]	郭业兵, 郑金峰. 阴道壁胃肠道外间质瘤一例报道并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 405-407.
[11]	中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下骨质疏松症管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 133-135.
[12]	王刚, 陈生弟. 神经病学的诊断：起源、发展及挑战[J]. 诊断学理论与实践, 2022, 21(01): 1-4.
[13]	唐静仪, 余群, 刘军. 结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展[J]. 诊断学理论与实践, 2022, 21(01): 12-17.
[14]	魏文石. 直面我国阿尔茨海默病诊治的挑战——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 5-7.
[15]	王蔚, 王小钦. 缺铁性贫血的病因诊断[J]. 诊断学理论与实践, 2021, 20(06): 529-532.